The ability to effectively deliver genetic material to vascular endothelial cells remains one of the greatest unmet challenges facing the development of gene therapies to prevent diseases with underlying vascular etiology, such as diabetes, atherosclerosis, and age-related macular degeneration. Herein, we assess the effectiveness of an rAAV2-based capsid mutant vector (Y272F, Y444F, Y500F, Y730F, T491V; termed QuadYF+TV) with strong endothelial cell tropism at transducing the vasculature after systemic administration. Intravenous injection of QuadYF+TV resulted in widespread transduction throughout the vasculature of several major organ systems, as assessed by in vivo bioluminescence imaging and postmortem histology. Robust transduction of lung tissue was observed in QuadYF+TV-injected mice, indicating a role for intravenous gene delivery in the treatment of chronic diseases presenting with pulmonary complications, such as α1-antitrypsin deficiency. The QuadYF+TV vector cross-reacted strongly with AAV2 neutralizing antibodies, however, indicating that a targeted delivery strategy may be required to maximize clinical translatability.
Get full access to this article
View all access options for this article.
References
1.
HamiltonSJ, and WattsGF. Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment. Rev Diabet Stud, 2013; 10:133–156.
2.
PudduP, PudduGM, ZacaF, et al.Endothelial dysfunction in hypertension. Acta Cardiol, 2000; 55:221–232.
3.
LiH, HorkeS, and ForstermannU. Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis, 2014; 237:208–219.
4.
HadiHA, CarrCS, and Al SuwaidiJ. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag, 2005; 1:183–198.
5.
TianXL, and LiY. Endothelial cell senescence and age-related vascular diseases. J Genet Genomics, 2014; 41:485–495.
6.
SchiffrinEL. Correction of remodeling and function of small arteries in human hypertension by cilazapril, an angiotensin I-converting enzyme inhibitor. J Cardiovasc Pharmacol, 1996; 27(Suppl 2):S13–S18.
7.
SchiffrinEL, ParkJB, IntenganHD, et al.Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation, 2000; 101:1653–1659.
8.
HornigB, LandmesserU, KohlerC, et al.Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation, 2001; 103:799–805.
9.
PrasadA, Tupas-HabibT, SchenkeWH, et al.Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation, 2000; 101:2349–2354.
10.
McFarlaneR, McCredieRJ, BonneyMA, et al.Angiotensin converting enzyme inhibition and arterial endothelial function in adults with type 1 diabetes mellitus. Diabet Med, 1999; 16:62–66.
11.
BogerRH, Bode-BogerSM, SzubaA, et al.Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation, 1998; 98:1842–1847.
12.
QuyyumiAA, DakakN, DiodatiJG, et al.Effect of l-arginine on human coronary endothelium-dependent and physiologic vasodilation. J Am Coll Cardiol, 1997; 30:1220–1227.
13.
StroesE, KasteleinJ, CosentinoF, et al.Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest, 1997; 99:41–46.
14.
HeitzerT, KrohnK, AlbersS, et al.Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type II diabetes mellitus. Diabetologia, 2000; 43:1435–1438.
15.
HigashiY, SasakiS, NakagawaK, et al.Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am J Hypertens, 2002; 15:326–332.
16.
PistroschF, PassauerJ, FischerS, et al.In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care, 2004; 27:484–490.
17.
HerweijerH, and WolffJA. Progress and prospects: naked DNA gene transfer and therapy. Gene Ther, 2003; 10:453–458.
18.
BelloA, ChandA, AvilesJ, et al.Novel adeno-associated viruses derived from pig tissues transduce most major organs in mice. Sci Rep, 2014; 4:6644.
19.
ChenS, KapturczakM, LoilerSA, et al.Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors. Hum Gene Ther, 2005; 16:235–247.
NettelbeckDM, MillerDW, JeromeV, et al.Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol Ther, 2001; 3:882–891.
22.
SchiednerG, BlochW, HertelS, et al.A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum Gene Ther, 2003; 14:1631–1641.
23.
ManickanE, SmithJS, TianJ, et al.Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Mol Ther, 2006; 13:108–117.
24.
RyalsRC, BoyeSL, DinculescuA, et al.Quantifying transduction efficiencies of unmodified and tyrosine capsid mutant AAV vectors in vitro using two ocular cell lines. Mol Vis, 2011; 17:1090–1102.
25.
Petrs-SilvaH, DinculescuA, LiQ, et al.High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther, 2009; 17:463–471.
26.
KayCN, RyalsRC, AslanidiGV, et al.Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. PLoS One, 2013; 8:e62097.
27.
IidaA, TakinoN, MiyauchiH, et al.Systemic delivery of tyrosine-mutant AAV vectors results in robust transduction of neurons in adult mice. Biomed Res Int, 2013; 2013:974819.
28.
QiaoC, ZhangW, YuanZ, et al.Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle. Hum Gene Ther, 2010; 21:1343–1348.
29.
ZolotukhinS, ByrneBJ, MasonE, et al.Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther, 1999; 6:973–985.
30.
CaiJ, JiangWG, GrantMB, et al.Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem, 2006; 281:3604–3613.
31.
BoyeSE, AlexanderJJ, BoyeSL, et al.The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina. Hum Gene Ther, 2012; 23:1101–1115.
32.
YamashitaT, TakahashiA, and HonjinR. Spatial aspect of the mouse orbital venous sinus. Okajimas Folia Anat Jpn, 1980; 56:329–336.
33.
HurlbutGD, ZieglerRJ, NietupskiJB, et al.Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. Mol Ther, 2010; 18:1983–1994.
34.
MannoCS, PierceGF, ArrudaVR, et al.Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med, 2006; 12:342–347.
35.
TsengYS, and Agbandje-McKennaM. Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vectors. Front Immunol, 2014; 5:9.
36.
LiC, DiprimioN, BowlesDE, et al.Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. J Virol, 2012; 86:7752–7759.
37.
MoskalenkoM, ChenL, van RoeyM, et al.Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol, 2000; 74:1761–1766.
38.
HalbertCL, MillerAD, McNamaraS, et al.Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: implications for gene therapy using AAV vectors. Hum Gene Ther, 2006; 17:440–447.
39.
MingozziF, AnguelaXM, PavaniG, et al.Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med, 2013; 5:194ra92.
40.
StasiR, and ProvanD. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc, 2004; 79:504–522.
41.
MingozziF, ChenY, EdmonsonSC, et al.Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue. Gene Ther, 2013; 20:417–424.
42.
MonteilhetV, SahebS, BoutinS, et al.A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther, 2011; 19:2084–2091.
43.
SmithRH, LevyJR, and KotinRM. A simplified baculovirus–AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol Ther, 2009; 17:1888–1896.
44.
ClementN, KnopDR, and ByrneBJ. Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies. Hum Gene Ther, 2009; 20:796–806.
45.
AslanidiG, LambK, and ZolotukhinS. An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cells. Proc Natl Acad Sci U S A, 2009; 106:5059–5064.
46.
OguraT, MizukamiH, MimuroJ, et al.Utility of intraperitoneal administration as a route of AAV serotype 5 vector-mediated neonatal gene transfer. J Gene Med, 2006; 8:990–997.
47.
HudaF, KonnoA, MatsuzakiY, et al.Distinct transduction profiles in the CNS via three injection routes of AAV9 and the application to generation of a neurodegenerative mouse model. Mol Ther Methods Clin Dev, 2014; 1:14032.
48.
MoriS, TakeuchiT, EnomotoY, et al.Biodistribution of a low dose of intravenously administered AAV-2, 10, and 11 vectors to cynomolgus monkeys. Jpn J Infect Dis, 2006; 59:285–293.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
